Keenova Therapeutics plc
14.20%
5,637,714
1567892
Apr 14, 2026
Apr 17, 2026, 05:41 PM
Reporting Persons (3)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Silver Point Capital, L.P. | Investment Adviser | 14.20% | 5,637,714 | 0 | 5,637,714 |
| Edward A. Mule | Individual | 14.20% | 5,637,714 | 0 | 5,637,714 |
| Robert J. O'Shea | Individual | 14.20% | 5,637,714 | 0 | 5,637,714 |
Disclosure Items (4)
Common Stock, par value $0.01 per share
Keenova Therapeutics plc
College Business & Technology Park, Dublin 15, L2, D15 TX2V
Item 3 of the Schedule 13D is hereby supplemented as follows: The source of funds used in the acquisitions reported in Item 5 was working capital of the Reporting Persons.
The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Amendment are incorporated herein by reference. The Reporting Persons currently beneficially own 5,637,714 shares of Common Stock, representing 14.2% of the shares of Common Stock outstanding. As reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 15, 2026, as of April 8, 2026, there were 39,581,987 shares of Common Stock issued and outstanding.
The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Amendment are incorporated herein by reference.
The following sets forth all transactions in the Common Stock effected by the Reporting Persons during the last 60 days: On April 15, 2026, the Reporting Persons purchased 275,000 shares of Common Stock at a price per share of $88.50 in the open market through brokers. On April 17, 2026, the Reporting Persons purchased 410,000 shares of Common Stock at a price per share of $90.50 in the open market through brokers.
Other than as disclosed in Item 4, no person other than the Reporting Persons are known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Common Stock held by the Reporting Persons.
Not applicable.
Exhibit No. Description 1 Joint Filing Agreement, dated as of April 17, 2026, by and among the Reporting Persons 2 Power of Attorney of Robert J. O'Shea and Edward A. Mule (incorporated here by reference to Schedule 13G filed by Silver Point Capital, L.P., Edward A. Mule and Robert J. O'Shea with the Securities and Exchange Commission on February 16, 2016 relating to TopBuild Corp.)